

Dear Duchenne community,

It was wonderful to see many members of the community at the Parent Project Muscular Dystrophy (PPMD) Conference at the end of June in Orlando, Florida, USA. At the conference, on 29 June 2019, we provided an update on the Roche anti-myostatin (RG6206) clinical program. RG6206 is an adnectin fusion protein designed to bind to a protein called myostatin and potentially inhibit its function. RG6206 is currently under investigation to evaluate its efficacy, safety and tolerability in ambulatory boys with Duchenne Muscular Dystrophy. With this letter, we are pleased to update the broader community.

As of 3rd July 2019, enrollment in the WN40227 (SPITFIRE) pivotal study has been officially completed globally at 48 sites across the US, Canada, Argentina, Europe, Australia and Japan. A total of 166 boys with Duchenne between the ages of 6 and 11 were randomized. The list of clinical sites as well as study details can be found at [www.clinicaltrials.gov](http://www.clinicaltrials.gov) (reference NCT03039686, Roche study WN40227).

As with all our clinical research programs, we continue to monitor our studies to confirm they should continue as planned; as such, we will be reviewing the ongoing SPITFIRE study in October-November of this year. This review is specified per the study protocol and is not prompted by any event or monitoring trends. We will update the community after the review is complete.

As the study is an ongoing placebo-controlled trial, it is important the study remain blind to preserve its integrity. As long as the study is continuing, no data can be shared.

We are sincerely grateful for the continuous partnership of the Duchenne community and would like to thank all of our study participants and their families and caregivers. Roche is committed to working together with the Duchenne community to support the evolving needs of patients and their families.

- If you have any questions regarding your ongoing participation in the SPITFIRE study, please contact your study physician.
- If you are not in the SPITFIRE study, but have questions about RG6206, please contact [elena.zhuravleva.ez1@roche.com](mailto:elena.zhuravleva.ez1@roche.com).
- For more information on the ongoing SPITFIRE study please visit [ForPatients.roche.com](http://ForPatients.roche.com), searching for [Duchenne](#).

Warm regards,

A handwritten signature in blue ink, appearing to read "Elena", written in a cursive style.

Elena Zhuravleva, Patient Partnership Director, Rare Disease, Roche, Switzerland  
On behalf of the Roche Duchenne team